Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
Read the full post on Becker's Hospital Review – Healthcare News
Read the full post on Becker's Hospital Review – Healthcare News
Read the full post on Becker's Hospital Review – Healthcare News
Read the full post on Becker's Hospital Review – Healthcare News
The data is reassuring to people who got this shot.
After years of unstable funding, California’s 2022-23 budget will include a dramatic new investment in public health. Insiders say a powerhouse lobbying campaign made all the difference.
The approach, known as contingency management, has helped thousands of veterans kick the methedrine habit, but a federal government ruling has limited its use. California hopes to challenge that and make the treatment a Medi-Cal benefit.
Read the full post on Becker's Hospital Review – Healthcare News
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act, in an effort to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive new drug that might or might not slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of The Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
